Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF86OC
|
|||
| Drug Name |
Ziltivekimab
|
|||
| Indication | Heart failure [ICD-11: BD10-BD13] | Phase 3 | [1] | |
| Company |
Novo Nordisk
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05636176) HERMES: Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation. U.S.National Institutes of Health. | |||
| REF 2 | IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 May 29;397(10289):2060-2069. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.